These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 38125894)

  • 21. Safety, Efficacy, and Relapse of Nirmatrelvir-Ritonavir in Kidney Transplant Recipients Infected With SARS-CoV-2.
    Devresse A; Sébastien Briol ; De Greef J; Lemaitre F; Boland L; Haufroid V; Scohy A; Kabamba B; Yombi JC; Belkhir L; Darius T; Buemi A; De Potter K; Mantegazza R; Bearzatto B; Goffin E; Kanaan N
    Kidney Int Rep; 2022 Nov; 7(11):2356-2363. PubMed ID: 36060621
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of Huashi Baidu granule plus Nirmatrelvir-Ritonavir combination therapy in patients with high-risk factors infected with Omicron (B.1.1.529): A multi-arm single-center, open-label, randomized controlled trial.
    Yu Z; Zheng Y; Chen B; Lv J; Zhu X; Shang B; Xv Y; Tao R; Yang Y; Cong J; Li D; Wu H; Qv W; Zhang X; Xv C; Feng H; Yuan W; Gao Y
    Phytomedicine; 2023 Nov; 120():155025. PubMed ID: 37639813
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical, Virologic, and Immunologic Evaluation of Symptomatic Coronavirus Disease 2019 Rebound Following Nirmatrelvir/Ritonavir Treatment.
    Epling BP; Rocco JM; Boswell KL; Laidlaw E; Galindo F; Kellogg A; Das S; Roder A; Ghedin E; Kreitman A; Dewar RL; Kelly SEM; Kalish H; Rehman T; Highbarger J; Rupert A; Kocher G; Holbrook MR; Lisco A; Manion M; Koup RA; Sereti I
    Clin Infect Dis; 2023 Feb; 76(4):573-581. PubMed ID: 36200701
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of Nirmatrelvir/Ritonavir Treatment on Upper Respiratory Severe Acute Respiratory Syndrome Coronavirus 2 Reverse Transcription-Polymerase Chain Reaction (SARS-Cov-2 RT-PCR) Negative Conversion Rates Among High-Risk Patients With Coronavirus Disease 2019 (COVID-19).
    Li H; Gao M; You H; Zhang P; Pan Y; Li N; Qin L; Wang H; Li D; Li Y; Qiao H; Gu L; Xu S; Guo W; Wang N; Liu C; Gao P; Niu J; Cao J; Zheng Y
    Clin Infect Dis; 2023 Feb; 76(3):e148-e154. PubMed ID: 35870128
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
    Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
    Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-world effectiveness of nirmatrelvir-ritonavir versus azvudine in hospitalized patients with COVID-19 during the omicron wave in Beijing: a multicenter retrospective cohort study.
    Han X; Gao D; Li C; Yuan X; Cui J; Zhao W; Xie F; Wang K; Liu Y; Muo G; Xi N; Zheng M; Wang R; Xiao K; Zhao D; Zhang X; Han X; Wang B; Zhang T; Xie W; Xie L
    BMC Infect Dis; 2024 Jan; 24(1):57. PubMed ID: 38191304
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-life comparison of mortality in patients with SARS-CoV-2 infection at risk for clinical progression treated with molnupiravir or nirmatrelvir plus ritonavir during the Omicron era in Italy: a nationwide, cohort study.
    Torti C; Olimpieri PP; Bonfanti P; Tascini C; Celant S; Tacconi D; Nicastri E; Tacconelli E; Cacopardo B; Perrella A; Buccoliero GB; Parruti G; Bassetti M; Biagetti C; Giacometti A; Erne EM; Frontuto M; Lanzafame M; Summa V; Spagnoli A; Vestri A; Di Perri G; Russo P; Palù G
    Lancet Reg Health Eur; 2023 Aug; 31():100684. PubMed ID: 37547273
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcomes with and without outpatient SARS-CoV-2 treatment for patients with COVID-19 and systemic autoimmune rheumatic diseases: A retrospective cohort study.
    Qian G; Wang X; Patel NJ; Kawano Y; Fu X; Cook CE; Vanni KMM; Kowalski EN; Banasiak EP; Bade KJ; Srivatsan S; Williams ZK; Todd DJ; Weinblatt ME; Wallace ZS; Sparks JA
    medRxiv; 2022 Oct; ():. PubMed ID: 36324801
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Short-Term Effectiveness of Oral Nirmatrelvir/Ritonavir Against the SARS-CoV-2 Omicron Variant and Culture-Positive Viral Shedding.
    Lee E; Park S; Choi JP; Kim MK; Yang E; Ham SY; Lee S; Lee B; Yang JS; Park BK; Kim DS; Lee SY; Lee JY; Jang HC; Jeon J; Park SW
    J Korean Med Sci; 2023 Feb; 38(8):e59. PubMed ID: 36852855
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molnupiravir compared to nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registry.
    Salmanton-García J; Marchesi F; Koehler P; Weinbergerová B; Čolović N; Falces-Romero I; Buquicchio C; Farina F; van Praet J; Biernat MM; Itri F; Prezioso L; Tascini C; Vena A; Romano A; Delia M; Dávila-Valls J; Martín-Pérez S; Lavilla-Rubira E; Adžić-Vukičević T; García-Bordallo D; López-García A; Criscuolo M; Petzer V; Fracchiolla NS; Espigado I; Sili U; Meers S; Erben N; Cattaneo C; Tragiannidis A; Gavriilaki E; Schönlein M; Mitrovic M; Pantic N; Merelli M; Labrador J; Hernández-Rivas JÁ; Glenthøj A; Fouquet G; Del Principe MI; Dargenio M; Calbacho M; Besson C; Kohn M; Gräfe S; Hersby DS; Arellano E; Çolak GM; Wolf D; Marchetti M; Nordlander A; Blennow O; Cordoba R; Mišković B; Mladenović M; Bavastro M; Limongelli A; Rahimli L; Pagano L; Cornely OA
    Int J Antimicrob Agents; 2023 Oct; 62(4):106952. PubMed ID: 37582478
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nirmatrelvir and ritonavir combination against COVID-19 caused by omicron BA.2.2 in the elderly: A single-center large observational study.
    Chen C; Li R; Xing S; Cao L; Qu Y; Lv Q; Li X; Chen Z
    Immun Inflamm Dis; 2024 Apr; 12(4):e1232. PubMed ID: 38578027
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a (the base therapeutic regimen) in moderate to severe COVID-19: A structured summary of a study protocol for a randomized controlled l trial.
    Alavi Darazam I; Hatami F; Rabiei MM; Pourhoseingholi MA; Moradi O; Shokouhi S; Hajesmaeili MR; Shabani M; Irvani SSN
    Trials; 2020 Oct; 21(1):880. PubMed ID: 33106183
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of Paxlovid in COVID-19 treatment during the periods of SARS-CoV-2 Omicron BA.5 and BN.1 subvariant dominance in the Republic of Korea: a retrospective cohort study.
    Kim DH; Yoo MG; Kim NY; Choi SY; Jang M; An M; Jeong SJ; Kim J
    Osong Public Health Res Perspect; 2024 Apr; 15(2):137-149. PubMed ID: 38621766
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.
    Irvani SSN; Golmohammadi M; Pourhoseingholi MA; Shokouhi S; Darazam IA
    Trials; 2020 Jun; 21(1):473. PubMed ID: 32493468
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nirmatrelvir and ritonavir for inpatients with severe or critical COVID-19 beyond five days of symptom onset: a propensity score-matched, multicenter, retrospective cohort study.
    Zhang H; Tan X; Zhang Z; Wang C; Shi H; Li Y; Li J; Kang Y; Jin X; Liao X
    BMC Infect Dis; 2024 Jun; 24(1):597. PubMed ID: 38890575
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of Nirmatrelvir/Ritonavir for treating the Omicron variant of COVID-19.
    Qiu C; Wu Z; Liu X; Zhang Q; Wu L; Ye X; Zhou J; Shi J; Jiang X
    Front Med (Lausanne); 2023; 10():1161193. PubMed ID: 37521354
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID-19 Trial of Nirmatrelvir.
    Singh RSP; Toussi SS; Hackman F; Chan PL; Rao R; Allen R; Van Eyck L; Pawlak S; Kadar EP; Clark F; Shi H; Anderson AS; Binks M; Menon S; Nucci G; Bergman A
    Clin Pharmacol Ther; 2022 Jul; 112(1):101-111. PubMed ID: 35388471
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of Paxlovid on in-hospital outcomes and post-COVID-19 condition in adult patients infected with SARS-CoV-2 Omicron variant: A non-randomized controlled clinical trial.
    Xu J; Song J; Xie Z; Yang J; Wu D; Liu F; Zhao Y; Zang H; Zhao Y
    Medicine (Baltimore); 2023 Dec; 102(51):e36714. PubMed ID: 38134107
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Supratherapeutic INR During Treatment With Nirmatrelvir/Ritonavir and Warfarin and Acute Illness With COVID-19: A Case Report.
    Dowd-Green C; Brown D; Wilson A; Streiff M
    J Pharm Pract; 2024 Dec; 37(6):1414-1418. PubMed ID: 38803049
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.